Meeting
2021 ASCO Annual Meeting
Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial.
Authors
Jonathan Wade Goldman
University of California, Los Angeles, Los Angeles, CA
Jonathan Wade Goldman , Santiago Viteri Ramirez , Amit Mahipal , Jennifer Marie Marie Suga , Lisa DeFazio Eli , Alshad S. Lalani , Richard Bryce , Feng Xu , Naisargee Shah , Fairooz Kabbinavar , Valentina Boni , Barbara B. Haley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01953926
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9068)
DOI
10.1200/JCO.2021.39.15_suppl.9068
Abstract #
9068
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2020 ASCO Virtual Scientific Program
Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
First Author: Xiuning Le
Poster
2024 ASCO Annual Meeting
Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).
First Author: Shen Zhao
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi